Brief: Cabaletta Bio Receives Additional FDA Fast Track Designations For Caba-201 In Dermatomyositis And Systemic Sclerosis
08/01/2024 13:57
Jan 8 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES ADDITIONAL FDA FAST TRACK
DESIGNATIONS
FOR CABA-201 IN DERMATOMYOSITIS AND SYSTEMIC SCLEROSIS
Source text for Eikon: ID:nGNXbjBBlT
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview